Business Description
10x Genomics Inc
NAICS : 621999
SIC : 8099
6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
Description
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.05 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.93 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 14.46 | |||||
| Beneish M-Score | -2.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 36.1 | |||||
| 3-Year EBITDA Growth Rate | 44.1 | |||||
| 3-Year EPS without NRI Growth Rate | 28.5 | |||||
| 3-Year FCF Growth Rate | -3.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 24.08 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.85 | |||||
| 9-Day RSI | 71.3 | |||||
| 14-Day RSI | 62.43 | |||||
| 6-1 Month Momentum % | -62.33 | |||||
| 12-1 Month Momentum % | -77.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.65 | |||||
| Quick Ratio | 5.05 | |||||
| Cash Ratio | 4.24 | |||||
| Days Inventory | 200.73 | |||||
| Days Sales Outstanding | 55.14 | |||||
| Days Payable | 66.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 78.85 | |||||
| Operating Margin % | -27.43 | |||||
| Net Margin % | -28.62 | |||||
| ROE % | -17.84 | |||||
| ROA % | -14.27 | |||||
| ROIC % | -39.56 | |||||
| ROC (Joel Greenblatt) % | -48.08 | |||||
| ROCE % | -15.43 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.74 | |||||
| PB Ratio | 6.91 | |||||
| Price-to-Tangible-Book | 7.18 | |||||
| EV-to-EBIT | -36.48 | |||||
| EV-to-Forward-EBIT | -31.86 | |||||
| EV-to-EBITDA | -47.11 | |||||
| EV-to-Revenue | 10.08 | |||||
| EV-to-Forward-Revenue | 9.69 | |||||
| EV-to-FCF | -31.57 | |||||
| Price-to-Net-Current-Asset-Value | 12.08 | |||||
| Price-to-Net-Cash | 19.26 | |||||
| Earnings Yield (Greenblatt) % | -2.74 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:TXG
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 497.932 | ||
| EPS (TTM) ($) | -1.26 | ||
| Beta | 0 | ||
| Volatility % | 50.28 | ||
| 14-Day RSI | 62.43 | ||
| 14-Day ATR ($) | 3.258167 | ||
| 20-Day SMA ($) | 41.0325 | ||
| 12-1 Month Momentum % | -77.6 | ||
| 52-Week Range ($) | 33.3 - 191.1525 | ||
| Shares Outstanding (Mil) | 113.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
10x Genomics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||